This filing is the full transcript of Eli Lilly's Q2 2026 earnings call, detailing robust revenue growth, raised full-year guidance, and significant pipeline advancements. The strong performance of key products, particularly incretins, and strategic acquisitions indicate continued positive momentum for the company.
Eli Lilly's Q2 2026 earnings call transcript reveals a very strong quarter with 48% revenue growth year-over-year and a significant increase in key product sales, especially in oncology, immunology, and neuroscience. The company raised its full-year guidance, indicating confidence in continued performance. Key drivers include the successful launch and expansion of Foundeo for obesity and type 2 diabetes, along with multiple regulatory approvals and positive clinical trial results for other pipeline assets. Strategic acquisitions further bolster future growth prospects. This news is highly positive for LLY, suggesting sustained growth and market leadership, particularly in the cardiometabolic space. For traders, this implies continued upward pressure on LLY stock in the short to medium term, with potential for further gains as pipeline assets mature and market access expands.